Literature DB >> 19224348

Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.

J M McGree1, J A Eccleston, S B Duffull.   

Abstract

We consider nested multiple response models which are used extensively in the area of pharmacometrics. Given the conditional nature of such models, differences in predicted responses are a consequence of different assumptions about how the models interact. As such, sequential versus simultaneous and First Order (FO) versus First Order Conditional Estimation (FOCE) techniques have been explored in the literature where it was found that the sequential and FO approaches can produce biased results. It is therefore of interest to determine any design consequences between the various methods and approximations. As optimal design for nonlinear mixed effects models is dependent upon initial parameter estimates and an approximation to the expected Fisher information matrix, it is necessary to incorporate any influence of nonlinearity (or parameter-effects curvature) into our exploration. Hence, sequential versus simultaneous design with FO and FOCE considerations are compared under low, typical and high degrees of nonlinearity. Additionally, predicted standard errors of parameters are also compared to empirical estimates formed via a simulation/estimation study in NONMEM. Initially, design theory for nested multiple response models is developed and approaches mentioned above are investigated by considering a pharmacokinetic-pharmacodynamic model found in the literature. We consider design for situations where all responses are continuous and extend this methodology to the case where a response may be a discrete random variable. In particular, for a binary response pharmacodynamic model, it is conjectured that such responses will offer little information about all parameters and hence a sequential optimization, in the form of product design optimality, may yield near optimal designs.

Mesh:

Year:  2009        PMID: 19224348     DOI: 10.1007/s10928-009-9113-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  9 in total

1.  Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan.

Authors:  I Nestorov; G Graham; S Duffull; L Aarons; E Fuseau; P Coates
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

2.  Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

Authors:  Sylvie Retout; France Mentré
Journal:  J Biopharm Stat       Date:  2003-05       Impact factor: 1.051

3.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

4.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

5.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.

Authors:  Andrew Hooker; Paolo Vicini
Journal:  AAPS J       Date:  2005-11-01       Impact factor: 4.009

6.  Optimal design for multivariate response pharmacokinetic models.

Authors:  Ivelina Gueorguieva; Leon Aarons; Kayode Ogungbenro; Karin M Jorga; Trudy Rodgers; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-21       Impact factor: 2.745

7.  Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

Authors:  M Tod; J M Rocchisani
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

8.  Some considerations on the design of population pharmacokinetic studies.

Authors:  Stephen Duffull; Tim Waterhouse; John Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

9.  Evaluation of uncertainty parameters estimated by different population PK software and methods.

Authors:  Céline Dartois; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Michel Tod; Pascal Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-10       Impact factor: 2.410

  9 in total
  3 in total

1.  Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Authors:  Camille Vong; Martin Bergstrand; Joakim Nyberg; Mats O Karlsson
Journal:  AAPS J       Date:  2012-02-17       Impact factor: 4.009

2.  Simultaneous optimal experimental design for in vitro binding parameter estimation.

Authors:  C Steven Ernest; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-13       Impact factor: 2.745

3.  A sequential Monte Carlo approach to derive sampling times and windows for population pharmacokinetic studies.

Authors:  J M McGree; C C Drovandi; A N Pettitt
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-31       Impact factor: 2.745

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.